Table 1.
Virus | NRP | Other receptor | Viral NRP-binding protein | Furin cleavage site | Infected cell lines and cells in vivo | Viral family | Genome | Host | Disease | Refs. |
SARS-CoV-2 | NRP-1 | ACE2 | S | Yes | HEK,* Caco2, Calu-3 | Coronaviridae | +RNA | Human | SARS | 33, 34 |
HTLV1 | NRP-1 | Glut-1, HSPG | Env | Yes | HeLa, DCs, T cells | Retroviridae | +RNA/DNA | Human | T cell leukemia | 35, 36 |
EBV | NRP-1 | Ephr-A2 | gB | Yes | Nasopharyngeal epithelial cells | Herpesviridae | DNA | Human | Nasopharyngeal cancer, lymphomas, mononucleosis | 37, 38 |
mCMV | NRP-1 | n.d. | n.d. | n.d. | Endothelial cells | Herpesviridae | DNA | Mouse | Mostly asymptomatic | 39 |
hCMV | NRP-2 | CD46 | Pentamer | n.d. | Nasopharyngeal epithelial and endothelial cells | Herpesviridae | DNA | Human | Birth complications, mononucleosis | 40 |
LUJV | NRP-2 | CD63/LAMP1 | GP | n.d. | Hap1, HEK, endothelial | Arenaviridae | −RNA | Human | Fatal hemorrhagic fever | 41, 42 |
SARS, severe acute respiratory syndrome; DCs, dendritic cells; n.d., not determined.
*HEK cells are susceptible to SARS-CoV-2 only after exogenous expression of ACE2 and TMPRSS2.